The CADMUS trial - Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer

File Description SizeFormat 
Trial paper CADMUS 2017 AG revisions Oct 2017.docxFile embargoed until 03 November 20181.36 MBMicrosoft Word    Request a copy
Title: The CADMUS trial - Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer
Author(s): Grey, A
Scott, R
Charman, S
Van der Meulen, J
Frinking, P
Acher, P
Liyanage, S
Madaan, S
Constantinescu, G
Shah, B
Graves, CB
Freeman, A
Jameson, C
Ramachandran, N
Emberton, M
Arya, M
Ahmed, HU
Item Type: Journal Article
Abstract: OBJECTIVE: To compare the proportion of clinically significant prostate cancers (PCa) found in lesions detected by multiparametric MRI (mpMRI) with that found in lesions detected by multiparametric ultrasound (mpUSS), in men at risk. PATIENTS AND METHODS: CADMUS (Cancer Detection by Multiparametric Ultrasound of the prostate) is a prospective, multi-centre paired cohort diagnostic utility study with built-in randomisation of order of biopsies. The trial is registered ISRCTN38541912. All patients will undergo the index test under evaluation (mpUSS±biopsies), as well as the standard test (mpMRI±biopsies). Eligible men will be those at risk of harbouring prostate cancer usually recommended for prostate biopsy, either for the first time or as a repeat, who have not had any prior treatment for prostate cancer. Men in need of repeat biopsy will include those with prior negative results but ongoing suspicion, and those with an existing prostate cancer diagnosis but a need for accurate risk stratification. Both scans will be reported blind to the results of the other and the order in which the targeted biopsies derived from the two different imaging modalities are taken will be randomized. Comparison will be drawn between biopsy results of lesions detected by mpUSS with those lesions detected by mpMRI. Agreement over position between the two imaging modalities will be studied. DISCUSSION: CADMUS will provide level one evidence on the performance of mpUSS derived targeted biopsies in the identification of clinically significant prostate cancer in comparison to mpMRI targeted biopsies. Recruitment is underway and expected to complete in 2018.
Publication Date: 3-Nov-2017
Date of Acceptance: 23-Oct-2017
URI: http://hdl.handle.net/10044/1/53753
DOI: https://dx.doi.org/10.1016/j.cct.2017.10.011
ISSN: 1551-7144
Publisher: Elsevier
Start Page: 86
End Page: 92
Journal / Book Title: Contemporary Clinical Trials
Volume: 66
Copyright Statement: © 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor/Funder: Wellcome Trust
Funder's Grant Number: 204998/Z/16/Z
Keywords: CADMUS
Multiparametric MRI
Multiparametric ultrasound
Prostate cancer
TRUS
Targeted prostate biopsy
Cadmus
Multiparametric MRI
Multiparametric ultrasound
Prostate cancer
TRUS
Targeted prostate biopsy
11 Medical And Health Sciences
General Clinical Medicine
Public Health
Publication Status: Published
Embargo Date: 2018-11-03
Appears in Collections:Division of Surgery
Faculty of Medicine



Items in Spiral are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons